2013


To access this material please log in or register

Register Authorize
2013/№5

Aldosterone inhibitors in multimodal therapy for heart failure in type 2 diabetes mellitus

Kondratjeva L. V.
“Russian Medical Academy of Postgraduate Education” of the RF Ministry of Health Care, Barrikadnaya 2/1, Moscow 123995

Keywords: aldosterone antaginists, treatment, type 2 diabetes mellitus, CHF

DOI: 10.18087/rhfj.2013.5.1856

The article presents pathogenetic options of CHF development in patients with type 2 DM, clinical studies demonstrating the need for using aldosterone antagonists, specifically eplerenone as the third neuro-hormonal modulator in addition to the ACEI and β-AB therapy to improve survival, reduce the risk of early and delayed mortality, reduce the frequency of hospitalizations, improve the prognosis, and decrease clinical symptoms in patients with type 2 DM and CHF (NYHA I–IV FC).
  1. A Race Against Time. The Challenge of Cardiovascular Disease in Developing Economies. Available at: http://earth.columbia.edu / news / 2004 / images / raceagainsttime_FINAL_051104.pdf
  2. Lee CD, Folsom AR, Pankow JS et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109 (7):855–860.
  3. Becker A, Bos G, de Vegt F et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10‑year follow-up of the Hoorn Study. Eur Heart J. 2003;24 (15):1406–1413.
  4. DeSouza C, Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov. 2009;8 (5):361–367.
  5. Campbell RK, White JR Jr. More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ. 2008; 34 (3):518–534.
  6. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100 (10):1132–1133.
  7. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100 (10):1134–1146.
  8. Clark CM Jr, Perry RC. Type 2 diabetes and macrovascular disease: epidemiology and etiology. Am Heart J. 1999;138 (5 Pt 1):S330–333.
  9. Thrainsdottir IS, Aspelund T, Hardarson T et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study. Eur J Cardiovasc Prev Rehabil. 2005;12 (5):465–471.
  10. De Groote P, Lamblin N, Mouquet F et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004;25 (8):656–662.
  11. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распростра­ненность хронической сердечной недостаточности в Европей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (3):112–115.
  12. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распростра­ненность хронической сердечной недостаточности в Европей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):4–7.
  13. Effect of intensive blood – glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):854–865.
  14. Chae CU, Pfeffer MA, Glynn RJ et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999;281 (7):634–639.
  15. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  16. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325 (5):293–302.
  17. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77 (11):1017–1020.
  18. Suskin N, McKelvie RS., Roteaus J et al. Increased insulin and glucose levels in heart failure. J Am Coll Cardiol. 1998;3 (Suppl): 249A.
  19. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. J Am Coll Cardiol. 1996;77 (11):1017–1020.
  20. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24 (9):1614–1619.
  21. Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 1997;23 (3):213–218.
  22. Мареев В. Ю. Фармакотерапия сердечной недостаточности при сахарном диабете. Журнал Сердечная Недостаточность. 2003;4 (1):50–51.
  23. Балаболкин М. И. Сахарный диабет. – М.: Медицина, 1994 –с.155–164.
  24. Александров А. А., Шацкая О. А., Кухаренко С. С. и другие. Сердечная недостаточность, сахарный диабет и риск гипогликемий: требуйте невозможного. Consilium medicum. 2011;12:59–65.
  25. Cоколов Е. И. Диабетическое сердце. – М.: Медицина, 2002–311с.
  26. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316 (23):1429–1435.
  27. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regu­lating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82 (5):1730–1736.
  28. Golestaneh N, Klein C, Valamanesh F et al. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun. 2001;280 (5):1300–1306.
  29. Farguharson CAJ, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in man: evidence for an aldosterone induced vasculopathy. Clin Sci (Lond). 2002;103 (4):425–431.
  30. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and rennin-angiotensin-aldosteron system. Circulation. 1991;83 (6):1849–1865.
  31. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
  32. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁ (c) levels in patients with chronic heart failure. Am Heart J. 2010;160 (5):915–921.
  33. Güder G, Bauersachs J, Frantz S et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115 (13):1754–1761.
  34. Yamaji M, Tsutamoto T, Kawahara C et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2 (6):608–615.
  35. Koizumi M, Yada T. Sub-chronic stimulation of glucocorticoid receptor impairs and mineralocorticoid receptor protects cytosolic Ca2+ responses to glucose in pancreatic beta-cells. J Endocrinol. 2008 May;197 (2):221–229.
  36. Preiss D, Zetterstrand S, McMurray JJ et al. Predictors of deve­lopment of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32 (5):915–920.
  37. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15 (8):709–716.
  38. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348 (14):1309–1321.
  39. Pitt B, White H, Nicolau J et al; EPHESUS Investigators. Eplerenone reduced mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46 (3):425–431.
  40. Solomon SD, Zelenkofske S, McMurray JJ et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352 (25):2581–2588.
  41. Zannad F, McMurray JJ, Krum H et al. for the EMPHASIS–HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21.
Kondratjeva L.V. Aldosterone inhibitors in multimodal therapy for heart failure in type 2 diabetes mellitus. Russian Heart Failure Journal. 2013;14 (5):277-283

To access this material please log in or register

Register Authorize
Ru En